SRR1323536
GTEX
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- GTEX
- cancer_type_detailed
- —
- subtype
- —
- cancer_type
- GTEX
- sex
- Female
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- ANGIOGENESIS+0.512
- INFLAMMATORY_RESPONSE+0.455
- TNFA_SIGNALING_VIA_NFKB+0.440
- KRAS_SIGNALING_UP+0.420
- ALLOGRAFT_REJECTION+0.391
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.360
- INTERFERON_GAMMA_RESPONSE+0.322
- IL6_JAK_STAT3_SIGNALING+0.320
- INTERFERON_ALPHA_RESPONSE+0.288
- COMPLEMENT+0.284
Top 10 suppressed
- MYC_TARGETS_V2-0.596
- OXIDATIVE_PHOSPHORYLATION-0.576
- MYC_TARGETS_V1-0.547
- DNA_REPAIR-0.505
- UNFOLDED_PROTEIN_RESPONSE-0.468
- E2F_TARGETS-0.418
- G2M_CHECKPOINT-0.370
- MTORC1_SIGNALING-0.328
- PROTEIN_SECRETION-0.317
- PI3K_AKT_MTOR_SIGNALING-0.283
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
8 twins match this tumor's tissue · 2 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR1408327 | GTEX | — | 0.951 |
| 2 | SRR1500800 | GTEX | — | 0.951 |
| 3 | SRR1368964 | GTEX | — | 0.949 |
| 4 | SRR1475675 | GTEX | — | 0.948 |
| 5 | SRR1329885 | GTEX | — | 0.947 |
| 6 | BS_HHPA8NJ2 | Med | Medulloblastoma | 0.946 |
| 7 | SRR1361795 | GTEX | — | 0.943 |
| 8 | SRR1472770 | GTEX | — | 0.942 |
| 9 | MDT-AP-1108 | Med | Medulloblastoma | 0.941 |
| 10 | SRR1467294 | GTEX | — | 0.941 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 30 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| ANGIOGENESIS | 0.512 | Remibrutinib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.455 | Idelalisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.440 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.420 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.391 | Idelalisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.360 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.322 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.320 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.288 | Inavolisib | — uncovered |
| COMPLEMENT | 0.284 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.281 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.265 | Idelalisib | — uncovered |
| COAGULATION | 0.248 | Binimetinib | — uncovered |
| KRAS_SIGNALING_DN | 0.238 | Remibrutinib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.227 | Idelalisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.202 | Cobimetinib | — uncovered |
| SPERMATOGENESIS | 0.202 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.197 | Temsirolimus | — uncovered |
| MYOGENESIS | 0.192 | Inavolisib | — uncovered |
| APOPTOSIS | 0.183 | Idelalisib | — uncovered |